MXPA03006266A - Uso de l-carnitina como agente estabilizador de proteinas. - Google Patents
Uso de l-carnitina como agente estabilizador de proteinas.Info
- Publication number
- MXPA03006266A MXPA03006266A MXPA03006266A MXPA03006266A MXPA03006266A MX PA03006266 A MXPA03006266 A MX PA03006266A MX PA03006266 A MXPA03006266 A MX PA03006266A MX PA03006266 A MXPA03006266 A MX PA03006266A MX PA03006266 A MXPA03006266 A MX PA03006266A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- carnitine
- stabilizing agent
- chaperone
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion se relaciona con el campo tecnico de la estabilizacion de proteinas, en particular con los aspectos terapeuticos de la estabilizacion de proteinas. La L-carnitina es un agente util para estabilizar proteinas, y en un aspecto particularmente favorable en proteinas usadas en el campo medico. En un aspecto preferido, la L-carnitina es usada para proteger la actividad de la chaperona, y en el campo medico para preservar la actividad y proteinas de chaperona alteradas. En relacion con esta invencion la L-carnitina es usada para preparacion de un medicamento para el tratamiento de enfermedades debidas a proteinas de chaperona alteradas, como enfermedades de los ojos, en particular cataratas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2000/000520 WO2002048190A1 (en) | 2000-12-15 | 2000-12-15 | Use of l-carnitine as stabilizing agent of proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03006266A true MXPA03006266A (es) | 2004-06-25 |
Family
ID=11133601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03006266A MXPA03006266A (es) | 2000-12-15 | 2000-12-15 | Uso de l-carnitina como agente estabilizador de proteinas. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7833977B2 (es) |
| EP (1) | EP1341813B1 (es) |
| AT (1) | ATE339445T1 (es) |
| AU (1) | AU2001223953A1 (es) |
| CA (1) | CA2434911C (es) |
| CY (1) | CY1106235T1 (es) |
| DE (1) | DE60030787T2 (es) |
| DK (1) | DK1341813T3 (es) |
| ES (1) | ES2272351T3 (es) |
| HU (1) | HU230002B1 (es) |
| MX (1) | MXPA03006266A (es) |
| PL (1) | PL199984B1 (es) |
| PT (1) | PT1341813E (es) |
| SK (1) | SK287787B6 (es) |
| WO (1) | WO2002048190A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531622A (ja) | 2000-05-03 | 2003-10-28 | エクスプレッシブ コンストラクツ，インコーポレイテッド | 組み換えタンパク質安定性および可溶性を改善する方法 |
| SK287787B6 (sk) | 2000-12-15 | 2011-09-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Použitie L-karnitínu ako stabilizačného činidla proteínov |
| EP1624886A2 (en) * | 2003-05-12 | 2006-02-15 | Expressive Constructs, Inc. | Methods for increasing cell and tissue viability |
| US8758802B2 (en) | 2009-12-14 | 2014-06-24 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US20200140500A1 (en) * | 2012-07-17 | 2020-05-07 | The Regents Of The University Of Michigan | High throughput methods, protein inhibitors, and uses thereof |
| EP2968239B1 (en) | 2013-03-14 | 2019-04-24 | The University of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| CN108348494A (zh) | 2015-11-13 | 2018-07-31 | 马萨诸塞大学 | 用于抑制白内障和老花眼的含peg的双官能分子 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1235153B (it) * | 1988-11-15 | 1992-06-22 | Sigma Tau Ind Farmaceuti | Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento |
| US20040058015A1 (en) * | 2000-06-01 | 2004-03-25 | Yuanjin Tao | Compositions and methods for treating eye discomfort and eye disease |
| SK287787B6 (sk) | 2000-12-15 | 2011-09-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Použitie L-karnitínu ako stabilizačného činidla proteínov |
| ITRM20010294A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
| US6923960B2 (en) * | 2001-10-03 | 2005-08-02 | Vsl Pharmaceuticals Inc. | Antioxidant combination composition and use thereof |
| US20050163873A1 (en) * | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| ITRM20040327A1 (it) * | 2004-07-01 | 2004-10-01 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici. |
| US8569366B2 (en) * | 2005-04-26 | 2013-10-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
-
2000
- 2000-12-15 SK SK890-2003A patent/SK287787B6/sk not_active IP Right Cessation
- 2000-12-15 WO PCT/IT2000/000520 patent/WO2002048190A1/en active IP Right Grant
- 2000-12-15 HU HU0400737A patent/HU230002B1/hu not_active IP Right Cessation
- 2000-12-15 MX MXPA03006266A patent/MXPA03006266A/es active IP Right Grant
- 2000-12-15 PT PT00987614T patent/PT1341813E/pt unknown
- 2000-12-15 US US10/470,999 patent/US7833977B2/en not_active Expired - Fee Related
- 2000-12-15 AU AU2001223953A patent/AU2001223953A1/en not_active Abandoned
- 2000-12-15 AT AT00987614T patent/ATE339445T1/de active
- 2000-12-15 PL PL367204A patent/PL199984B1/pl unknown
- 2000-12-15 ES ES00987614T patent/ES2272351T3/es not_active Expired - Lifetime
- 2000-12-15 CA CA002434911A patent/CA2434911C/en not_active Expired - Fee Related
- 2000-12-15 DE DE60030787T patent/DE60030787T2/de not_active Expired - Lifetime
- 2000-12-15 DK DK00987614T patent/DK1341813T3/da active
- 2000-12-15 EP EP00987614A patent/EP1341813B1/en not_active Expired - Lifetime
-
2006
- 2006-11-03 CY CY20061101592T patent/CY1106235T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK8902003A3 (en) | 2003-12-02 |
| CY1106235T1 (el) | 2011-06-08 |
| PL199984B1 (pl) | 2008-11-28 |
| HUP0400737A3 (en) | 2013-06-28 |
| ES2272351T3 (es) | 2007-05-01 |
| EP1341813A1 (en) | 2003-09-10 |
| WO2002048190A1 (en) | 2002-06-20 |
| AU2001223953A1 (en) | 2002-06-24 |
| ATE339445T1 (de) | 2006-10-15 |
| SK287787B6 (sk) | 2011-09-05 |
| DK1341813T3 (da) | 2007-01-15 |
| US7833977B2 (en) | 2010-11-16 |
| PT1341813E (pt) | 2007-01-31 |
| HU230002B1 (en) | 2015-04-28 |
| CA2434911A1 (en) | 2002-06-20 |
| EP1341813B1 (en) | 2006-09-13 |
| DE60030787T2 (de) | 2007-09-13 |
| CA2434911C (en) | 2009-12-08 |
| US20040120967A1 (en) | 2004-06-24 |
| HUP0400737A2 (hu) | 2004-07-28 |
| PL367204A1 (en) | 2005-02-21 |
| DE60030787D1 (de) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID24901A (id) | Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh | |
| AU766216C (en) | Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia | |
| BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
| TW200605909A (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
| WO2007025142A3 (en) | Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures | |
| AU2002341366A1 (en) | Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes | |
| NZ506408A (en) | Pharmaceutical compositions | |
| CY1106235T1 (el) | Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων | |
| WO2003063780A3 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
| ZA991749B (en) | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy. | |
| DE60043886D1 (de) | Formulierungen mit povidon-iod zur behandlung von wunden | |
| LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
| IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
| ES2182840T3 (es) | Factor xiii para el tratamiento de heridas de la piel. | |
| EP1361905B8 (en) | Matrix protein compositions for guided connective tissue growth | |
| ATE295159T1 (de) | Bupropion zur behandlung von viralen erkrankungen | |
| WO2001028578A3 (en) | A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME | |
| WO2001070951A3 (de) | Mittel zur diagnose und therapie viraler erkrankungen | |
| AU2003294834A1 (en) | Anthranilic acid amide derivatives and their pharmaceutical use | |
| WO2003097690A3 (en) | Pth derivatives resistant to skin proteases | |
| DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
| RU2000101091A (ru) | Способ лечения дистрофических заболеваний сетчатки и зрительного нерва | |
| DE60040910D1 (de) | Inaktivierte zytokine zur immunisierung | |
| RU94000695A (ru) | Средство с противоаллергическим действием | |
| Berger | Body composition changes with protease therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |